PARP1 inhibition elicits immune responses against non-small cell lung cancer. (31st December 2022)

• Record Type: Journal Article
• Authors: Juncheng, Pan; Lafarge, Antoine; Kroemer, Guido; Castedo, Maria
• Is Part Of: Oncoimmunology. Volume 11:Number 1(2022)
• Publication Date: 2022-12-31
• Subjects: Anticancer immune response -- metabolism -- tumor microenvironment -- immune escape -- non-small cell lung cancer; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2022.2111915
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: High levels of intracellular poly(ADP-ribose) (PAR) resulting from an elevated activity of PAR polymerase-1 (PARP1) correlate with poor infiltration of non-small cell lung cancers by cytotoxic T lymphocytes and dismal patient prognosis. Preclinical experimentation now demonstrates that PARP1 inhibition in cancer cells mediates strong immunostimulatory effects.